(RTTNews) – Novavax, Inc. (NVAX) announced that the Nuvaxovid COVID-19 vaccine has won expanded production and marketing approval in Japan to prevent COVID-19 in adolescents ages 12 to 17. Nuvaxovid was previously approved in Japan for others over the age of 18.
The company partnered with Takeda to develop, manufacture and distribute Nuvaxovid in Japan. Novavax has legalized and transferred its production technologies and offers Matrix-M adjuvant to allow Takeda to manufacture the vaccine at its plant.
In addition, Novavax announced that the Australian Therapeutic Goods Agency granted expanded approval for the provisional registration of the Nuvaxovid COVID-19 vaccine for active immunization to save you from COVID-19 in adolescents over the ages of 12 to 17. The company’s sponsor in Australia is Biocelect Pty. Ltd.
For more health facts, rttnews. com.